GILEAD SCIENCES INC Insider Trading for February 2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in GILEAD SCIENCES INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in GILEAD SCIENCES INC for February 2015.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 0.00 | 57,632 | 0 | 101,471 | 43.8 K to 101.5 K (+131.46 %) |
| Feb 27 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Gift | G | 0.00 | 57,632 | 0 | 27,724 | 85.4 K to 27.7 K (-67.52 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Option Exercise | M | 16.40 | 70,000 | 1,147,650 | 20,000 | |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 103.26 | 40,886 | 4,222,048 | 165,168 | 206.1 K to 165.2 K (-19.84 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 102.66 | 29,114 | 2,988,692 | 206,054 | 235.2 K to 206.1 K (-12.38 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Buy | M | 16.40 | 70,000 | 1,147,650 | 235,168 | 165.2 K to 235.2 K (+42.38 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Payment of Exercise | F | 103.84 | 244,205 | 25,358,247 | 4,255,876 | 4.5 M to 4.3 M (-5.43 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Grant | A | 0.00 | 312,000 | 0 | 4,500,081 | 4.2 M to 4.5 M (+7.45 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Grant | A | 0.00 | 64,846 | 0 | 4,188,081 | 4.1 M to 4.2 M (+1.57 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Grant | A | 85.61 | 248 | 21,232 | 4,123,235 | 4.1 M to 4.1 M (+0.01 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Payment of Exercise | F | 103.84 | 106,970 | 11,107,765 | 1,029,108 | 1.1 M to 1 M (-9.42 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Grant | A | 0.00 | 136,668 | 0 | 1,136,078 | 999.4 K to 1.1 M (+13.67 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Grant | A | 0.00 | 25,114 | 0 | 999,410 | 974.3 K to 999.4 K (+2.58 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Grant | A | 85.61 | 248 | 21,232 | 974,296 | 974 K to 974.3 K (+0.03 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Payment of Exercise | F | 103.84 | 62,616 | 6,502,045 | 85,356 | 148 K to 85.4 K (-42.32 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 0.00 | 80,000 | 0 | 147,972 | 68 K to 148 K (+117.70 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 0.00 | 17,892 | 0 | 67,972 | 50.1 K to 68 K (+35.73 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 85.61 | 248 | 21,232 | 50,080 | 49.8 K to 50.1 K (+0.50 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Payment of Exercise | F | 103.84 | 16,157 | 1,677,743 | 45,439 | 61.6 K to 45.4 K (-26.23 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 0.00 | 19,200 | 0 | 61,596 | 42.4 K to 61.6 K (+45.29 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 0.00 | 7,840 | 0 | 42,396 | 34.6 K to 42.4 K (+22.69 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 85.61 | 248 | 21,232 | 34,556 | 34.3 K to 34.6 K (+0.72 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Payment of Exercise | F | 103.84 | 66,794 | 6,935,889 | 149,422 | 216.2 K to 149.4 K (-30.89 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Grant | A | 0.00 | 85,334 | 0 | 216,216 | 130.9 K to 216.2 K (+65.20 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Grant | A | 0.00 | 18,940 | 0 | 130,882 | 111.9 K to 130.9 K (+16.92 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Grant | A | 85.61 | 248 | 21,232 | 111,942 | 111.7 K to 111.9 K (+0.22 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Payment of Exercise | F | 103.84 | 83,490 | 8,669,602 | 165,168 | 248.7 K to 165.2 K (-33.58 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 0.00 | 106,668 | 0 | 248,658 | 142 K to 248.7 K (+75.12 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 0.00 | 22,440 | 0 | 141,990 | 119.6 K to 142 K (+18.77 %) |
| Feb 19 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 85.61 | 248 | 21,232 | 119,550 | 119.3 K to 119.6 K (+0.21 %) |
| Feb 10 2015 | GILD | GILEAD SCIENCES IN ... | WOLD OLSEN PER | Director | Buy | P | 99.92 | 10,000 | 999,150 | 88,173 | 78.2 K to 88.2 K (+12.79 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 80.65 | 2,000 | 161,300 | 36,640 | |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 106.16 | 2,000 | 212,310 | 34,308 | 36.3 K to 34.3 K (-5.51 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 80.65 | 2,000 | 161,300 | 36,308 | 34.3 K to 36.3 K (+5.83 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 40.56 | 5,592 | 226,812 | 44,750 | |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 24.30 | 11,250 | 273,319 | 45,000 | |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 23.76 | 4,800 | 114,024 | 0 | |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 19.09 | 11,550 | 220,432 | 0 | |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 106.85 | 600 | 64,111 | 49,832 | 50.4 K to 49.8 K (-1.19 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 105.98 | 8,200 | 869,027 | 50,432 | 58.6 K to 50.4 K (-13.99 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 105.14 | 24,392 | 2,564,524 | 58,632 | 83 K to 58.6 K (-29.38 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 40.56 | 5,592 | 226,812 | 83,024 | 77.4 K to 83 K (+7.22 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 24.30 | 11,250 | 273,319 | 77,432 | 66.2 K to 77.4 K (+17.00 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 23.76 | 4,800 | 114,024 | 66,182 | 61.4 K to 66.2 K (+7.82 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 19.09 | 11,550 | 220,432 | 61,382 | 49.8 K to 61.4 K (+23.18 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | M | 19.09 | 10,000 | 190,850 | 54,375 | |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 106.35 | 500 | 53,176 | 111,694 | 112.2 K to 111.7 K (-0.45 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 105.27 | 1,500 | 157,900 | 112,194 | 113.7 K to 112.2 K (-1.32 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 107.03 | 100 | 10,703 | 113,694 | 113.8 K to 113.7 K (-0.09 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 106.07 | 6,270 | 665,054 | 113,794 | 120.1 K to 113.8 K (-5.22 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 105.20 | 3,630 | 381,886 | 120,064 | 123.7 K to 120.1 K (-2.93 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Buy | M | 19.09 | 10,000 | 190,850 | 123,694 | 113.7 K to 123.7 K (+8.80 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 14.50 | 150,000 | 2,175,375 | 1,500,000 | |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 106.81 | 4,067 | 434,388 | 4,122,987 | 4.1 M to 4.1 M (-0.10 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 105.99 | 44,733 | 4,741,219 | 4,127,054 | 4.2 M to 4.1 M (-1.07 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 105.14 | 101,200 | 10,639,642 | 4,171,787 | 4.3 M to 4.2 M (-2.37 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 14.50 | 150,000 | 2,175,375 | 4,272,987 | 4.1 M to 4.3 M (+3.64 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Option Exercise | M | 26.99 | 5,000 | 134,950 | 5,000 | |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Sell | S | 106.82 | 800 | 85,452 | 15,641 | 16.4 K to 15.6 K (-4.87 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Sell | S | 106.04 | 1,400 | 148,459 | 16,441 | 17.8 K to 16.4 K (-7.85 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Sell | S | 105.16 | 2,800 | 294,447 | 17,841 | 20.6 K to 17.8 K (-13.57 %) |
| Feb 04 2015 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Buy | M | 26.99 | 5,000 | 134,950 | 20,641 | 15.6 K to 20.6 K (+31.97 %) |
| Feb 03 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | A | 104.83 | 169,820 | 17,802,231 | 169,820 | |
| Feb 03 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | A | 104.83 | 51,690 | 5,418,663 | 51,690 | |
| Feb 03 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Option Exercise | A | 104.83 | 70,290 | 7,368,501 | 70,290 | |
| Feb 03 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Option Exercise | A | 104.83 | 62,020 | 6,501,557 | 62,020 | |
| Feb 03 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | A | 104.83 | 47,260 | 4,954,266 | 47,260 | |
| Feb 03 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | A | 104.83 | 44,300 | 4,643,969 | 44,300 |